WEST PHARMACEUTICAL SERVICES INC
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
Earnings
Next report expected Oct 22, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 23, 2026 | Before market open | $872.30M | $2.15 | $2.37 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 23, 2026 | Before market open | $844.90M | $1.92 | $2.13 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $805.00M | $1.82 | $2.04 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 23, 2025 | Before market open | $804.60M | $1.92 | $1.96 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 24, 2025 | Before market open | $766.50M | $1.82 | $1.84 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | Before market open | $698.00M | $1.23 | $1.45 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | $748.80M | $1.78 | $1.82 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 24, 2024 | Before market open | $746.90M | $1.85 | $1.85 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 25, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 25, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 23, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital spending | full-year 2026 | $250.00M to $275.00M | Maintained |
| adjusted-diluted EPSnon-GAAP | Full-year 2026 | $8.85 to $9.05 | Raised |
| adjusted-diluted EPSnon-GAAP | third-quarter 2026 | $2.14 to $2.24 | New |
| Reported-diluted EPS (U.S. GAAP)GAAP | 2026 | $9.01 to $9.26 | Raised |
| Reported net sales growthGAAP | full-year 2026 | 8.8% to 10% growth | New |
| organic net sales growthnon-GAAP | full-year 2026 | 10% to 11% growth | Raised |
| net salesGAAP | Full-year 2026 | $3.35B to $3.38B | New |
| Reported net sales growthGAAP | third-quarter 2026 | 1.9% to 3.8% growth | New |
| organic net sales growthnon-GAAP | third-quarter 2026 | 7% to 8.9% growth | New |
| net salesGAAP | third-quarter 2026 | $820.00M to $835.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements West Pharmaceutical Services filed with the SEC
West Reports Second-Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bob W. McMahon Senior VP & Chief Financial Officer Second-Quarter 2026 Earnings Call July 23, 2026 | 8 a.m. Eastern Time
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
West Reports First-Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President, CEO & Chair of the Board Bob W. McMahon Senior Vice President & Chief Financial Officer First-Quarter 2026 Earnings Call April 23, 2026 | 8 a.m. Eastern Time
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
West Reports Fourth-Quarter and Full-Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bob W. McMahon Senior VP & Chief Financial Officer Fourth-Quarter and Full-Year 2025 Earnings Call February 12, 2026 | 8 a.m. Eastern Time
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Reports Third-Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bob W. McMahon Senior VP & Chief Financial Officer Third-Quarter 2025 Earnings Call October 23, 2025 | 8 a.m. Eastern Time
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial Officer Second-Quarter Results 2025 Analyst Conference Call 8 a.m. Eastern Time | July 24, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial Officer First-Quarter Results 2025 Analyst Conference Call 9 a.m. Eastern Time | April 24, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Fourth-Quarter and Full-Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial Officer Fourth-Quarter and Full Year Results 2024 Analyst Conference Call 9 a.m. Eastern Time | February 13, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Elects New Director to the Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial Officer Third-Quarter Results 2024 Analyst Conference Call 9 a.m. Eastern Time | October 24, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Second-Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial Officer Second-Quarter Results 2024 Analyst Conference Call 9 a.m. Eastern Time | July 25, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces First-Quarter 2024 Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer First-Quarter Results 2024 Analyst Conference Call 9 a.m. Eastern Time | April 25, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Fourth-Quarter and Full-Year 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
7 2024 Full-Year Guidance WST Q4/FY 2023 Earnings 2024 Full-Year Guidance Consolidated Net Sales $3.000 - $3.025 billion Adjusted-Diluted EPS $7.50 to $7.75
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer Third-Quarter 2023 Analyst Conference Call 9 a.m. Eastern Time | October 26, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Second-Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer Second-Quarter 2023 Analyst Conference Call 9 a.m. Eastern Time | July 27, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces First-Quarter 2023 Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer First-Quarter 2023 Analyst Conference Call 9 a.m. Eastern Time | April 27, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Fourth-Quarter and Full-Year 2022 Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
West Announces Third-Quarter 2022 Results, Updates Full-Year 2022 Guidance and Declares Fourth-Quarter 2022 Dividend
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer Third-Quarter Results 2022 Analyst Conference Call 9 a.m. Eastern Time | October 27, 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Announces Second-Quarter 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
West Pharmaceutical Services, Inc. Eric M. Green President & CEO, Chair of the Board Bernard J. Birkett Senior VP & Chief Financial and Operations Officer Second-Quarter Results 2022 Analyst Conference Call 9 a.m. Eastern Time | July 28, 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
West Elects New Director to the Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
West Announces Executive Leadership Appointments
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K